TGA decision on scheduling of injectable meloxicam

AVA members can rest assured that their voices have been heard:  the Therapeutic Goods Administration (TGA) announced last night they have made an interim decision to not amend the current scheduling of injectable meloxicam from S4 to S6. 

There were a total of 333 public submissions; of these 309 were opposed to the rescheduling. The submissions by the AVA and the special interest groups of the AVA, along with the Racing Australia submission were specifically noted as having influenced the TGA’s decision.  The full decision can be read here.

AVA Members can log into the website (link in the menu) to read more about the AVA's work on this topic, on this page.